Recent Updates
Recently added Catalysts

HMB-003

Phase 1

Healthy Adult Participants | Small molecule | Other |Hemab Therapeutics Holdings, Inc.|Last Updated: Sep 10, 2026

Target and mechanism

Molecular targetplasmin
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Clinical trial landscape

HMB-003 · 1 trial · 1 indication

Phase 1 1
NCT07798505A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy VolunteersHealthy Adult Participants
RECRUITING40 Analytics
PHASE1RECRUITING
A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers
Healthy Adult Participants
NCT0779850540
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with treatment emergent adverse events (TEAEs)
From Day 1 up to 42 days after a single dose of study drug on Day 1

Secondary Endpoints

Plasma concentration of HMB-003
From 0 hours (pre-dose) to 42 days after a single dose on Day 1
Urine concentration of HMB-003
From 0 hours (pre-dose) to 42 days after a single dose on Day 1
Pharmacodynamic parameter: Clot lysis
From 0 hours (pre-dose) to 42 days after a single dose on Day 1
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
HMB-003EXPERIMENTALParticipants will be administered a single dose of HMB-003 at an escalating dose level according to the assigned cohort.
PlaceboPLACEBO_COMPARATORParticipants will be administered a single dose

Interventions

NameTypeDescription
HMB-003DRUGHMB-003 will be administered subcutaneously as a single dose
PlaceboDRUGPlacebo will be administered subcutaneously as a single dose of placebo.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent. * Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG. Exclusion Criteria: * Participant has a history of clinically...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 10, 2026NCT07798505Status: NOT_YET_RECRUITING → RECRUITING
LOWSep 10, 2026NCT07798505Status: NOT_YET_RECRUITING → RECRUITING

Other drugs targeting plasmin

ALN-6400 ALNY· PHASE2 JX10 MIST· PHASE2